CMS to exclusively distribute two Vifor products in China
Vifor Pharma has entered into an exclusive distribution agreement with China Medical System Holdings (CMS) for the former's products, Uro-Vaxom and Maltofer. Under the agreement, CMS will have rights to distribute the products in the People's Republic of China, excluding Hong Kong, Macao and Taiwan. CMS will also assume responsibility for registering the products in China. The agreement is for ten years from the date of the first commercialisation of the products in China, and will be automatically extended for a further five years if certain sales targets are met.
Uro-Vaxom is an extract Escherichia coli for the treatment and prevention of recurrent urinary tract infections that stimulates the immune system and the body's natural defence against urinary pathogens. Maltofer is an oral iron supplement developed by Vifor for the treatment of iron deficiency without anaemia and iron deficiency anaemia, which has been marketed globally in more than 80 countries.